Low rates of retained gastric contents were seen in endoscopy patients on GLP-1 receptor agonists ( RAs), a retrospective ...

Copycats and false advertisements are also to blame for the increased threats. Stemming from social media testimonials all ...

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for ...

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

Significant’ weight returned weeks after stopping drug, say researchers who advise patients to adjust expectations.

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

Consumers are the only ones struggling to pay the rising prices of popular GLP-1 drugs, as states like Connecticut see ...

For patients with type 2 diabetes, GLP-1 RAs are associated with an increased risk for GERD and its complications compared with SGLT-2 inhibitors.

“This is the first major study to compare the effect of two common diabetes treatments — GLP-1 medicines and metformin — on dementia risk, using health records from more than 174,000 people. The ...